Jukes Namm (@drjukesnamm) 's Twitter Profile
Jukes Namm

@drjukesnamm

Surgical Oncologist & Ethicist #surgethics @LLUHealth | Associate Professor, Program Director of Surgery, Director of Clinical Ethics | Tweets are my own

ID: 4779527791

linkhttp://www.llusurgery.org calendar_today18-01-2016 18:33:59

483 Tweet

369 Takipçi

249 Takip Edilen

Jukes Namm (@drjukesnamm) 's Twitter Profile Photo

Thank you Jonathan M. Metzl for creating community with us Loma Linda U. Health. We’ll play some softball next time. #DyingofWhiteness #HighwaysandHedges #AdventistBioethicsConference2023

Thank you <a href="/JonathanMetzl/">Jonathan M. Metzl</a> for creating community with us <a href="/LLUHealth/">Loma Linda U. Health</a>. We’ll play some softball next time. #DyingofWhiteness #HighwaysandHedges #AdventistBioethicsConference2023
Jukes Namm (@drjukesnamm) 's Twitter Profile Photo

Congratulations to Dr. Matthew Whealon and Frank Lee on bringing the Tanzini Trophy to UC Irvine Surgery! Michael O'Leary MD and our outstanding prelim PGY2 Ayaa Ali presented robust evidence for #WatchandWait after #TNT, but I guess surgeons like to operate! 🤷🏻‍♂️ SoCal Chapter - American College of Surgeons

Jukes Namm (@drjukesnamm) 's Twitter Profile Photo

Hot take SoCal Chapter - American College of Surgeons by Zachary Tran, MD on the use of #REBOA for placenta accreta. ⬆️ GI complications, ⬆️ arterial embolism, ⬆️ cost, and no difference in blood transfusion rates. More investigative “labor” is needed. Sharon Lum MD MBA FACS #SCCACS2024

Hot take <a href="/SoCalSurgeons/">SoCal Chapter - American College of Surgeons</a> by <a href="/DrZacharyTran/">Zachary Tran, MD</a> on the use of #REBOA for placenta accreta. ⬆️ GI complications, ⬆️ arterial embolism, ⬆️ cost, and no difference in blood transfusion rates. More investigative “labor” is needed. <a href="/DrSharonLum/">Sharon Lum MD MBA FACS</a> #SCCACS2024
Jeff Matthews MD (@jbmatthews) 's Twitter Profile Photo

ASA/ASC Blue Ribbon Panel II on Surgical Education now available open access Annals of Surgery. I hope this helps point the way to improve surgical training for the next generation. We have much to do. journals.lww.com/annalsofsurger…

NEJM (@nejm) 's Twitter Profile Photo

Presented at #ASCO24: Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event-free survival was 83.7%, as compared with 57.2% among those who received only adjuvant therapy. Full NADINA trial results: nej.md/3wSo3uk

Presented at #ASCO24: 

Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event-free survival was 83.7%, as compared with 57.2% among those who received only adjuvant therapy. Full NADINA trial results: nej.md/3wSo3uk
NEJM (@nejm) 's Twitter Profile Photo

Neoadjuvant nivolumab plus ipilimumab results in a substantial pathological response in most patients with mismatch repair–deficient colon cancer and appears to be safe. Read the full NICHE-2 phase 2 study results: nej.md/3Ku4X0H

Neoadjuvant nivolumab plus ipilimumab results in a substantial pathological response in most patients with mismatch repair–deficient colon cancer and appears to be safe. Read the full NICHE-2 phase 2 study results: nej.md/3Ku4X0H
Jukes Namm (@drjukesnamm) 's Twitter Profile Photo

Honored to have Dr. Wanda Lam share her experience as a PAACS global surgeon at Nkhoma Mission Hospital in Malawi! Inspiring the next generation of global surgery leaders Loma Linda U. Health Serge

Honored to have Dr. Wanda Lam share her experience as a <a href="/PAACS_/">PAACS</a> global surgeon at Nkhoma Mission Hospital in Malawi! Inspiring the next generation of global surgery leaders <a href="/LLUHealth/">Loma Linda U. Health</a> <a href="/GraceAtTheFray/">Serge</a>